Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study

We sought to expand upon preliminary data suggesting that metformin confers a survival benefit to patients with head and neck squamous cell carcinoma (HNSCC). A large-scale retrospective cohort study of all patients in Ontario diagnosed with squamous cancer of the larynx, hypopharynx, and nasopharyn...

Full description

Saved in:
Bibliographic Details
Published in:Journal of otolaryngology 2018-12, Vol.47 (1), p.74-74
Main Authors: Quimby, Alexandra E, Lebo, Nicole L, Griffiths, Rebecca, Hall, Stephen, Dimitroulakos, Jim, Johnson-Obaseki, Stephanie
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antidiabetics
Cancer patients
Care and treatment
Comorbidity
Female
Head & neck cancer
Head and neck cancer
Health aspects
Health risk assessment
Human papillomavirus
Humans
Hypoglycemic Agents - therapeutic use
Hypopharynx
Kinases
Laryngeal cancer
Larynx
Male
Metformin
Metformin - therapeutic use
Nasopharynx
Original
Population-based studies
Retrospective Studies
Squamous cell carcinoma
Squamous Cell Carcinoma of Head and Neck - drug therapy
Squamous Cell Carcinoma of Head and Neck - mortality
Survival Analysis
Systematic review
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We sought to expand upon preliminary data suggesting that metformin confers a survival benefit to patients with head and neck squamous cell carcinoma (HNSCC). A large-scale retrospective cohort study of all patients in Ontario diagnosed with squamous cancer of the larynx, hypopharynx, and nasopharynx between Dec 1st 2007 to Dec 1st 2012 was undertaken. The Institute for Clinical and Evaluative Sciences was accessed to obtain patient demographic, treatment and outcome information. We included patients on metformin at the time of diagnosis. Kaplan Meier methods and Cox Regression models were used. Patients taking metformin at the time of diagnosis had a higher comorbid status but were otherwise similar to patients without metformin usage. Using multivariate analysis, neither overall survival nor disease specific survival was improved in patients on metformin (OS: HR 1.123, p = .338; DSS: HR 1.048, p = .792). No survival advantage was observed in patients with HNSCC taking metformin at the time of diagnosis.
ISSN:1916-0216
1916-0208
1916-0216
DOI:10.1186/s40463-018-0322-7